Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation

Neuropharmacology

Volumn 53, Issue 2, 2007, Pages 232-241

  Bruins Slot, Liesbeth A ^a   Palmier, Christiane ^a   Tardif, Stéphanie ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotics; Dopamine D3 receptor; ERK 1 2; G proteins; Schizophrenia

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; ARIPIPRAZOLE; BIFEPRUNOX; BP 897; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; F 15063; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NEUROLEPTIC AGENT; NORCLOZAPINE; OLANZAPINE; PRECLAMOL; QUINELORANE; RACLOPRIDE; S 33084; SARIZOTAN; SEROTONIN 1A RECEPTOR; SSR 181507; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, DOPAMINE D3; TRANSFECTION;

EID: 34547536635     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.05.006     Document Type: Article

References (50)

1. 1A agonist actions. I. Neurochemical effects. Neuropharmacology 39 (2000) 1197-1210
2. 1A agonist properties. Neuropsychopharmacology 31 (2006) 1869-1879
3. 1A affinity in rodent models of cognition and memory deficits: (I) the hole-board and social recognition tests. Int. J. Neuropsychopharmacol. 9 Suppl. 1 (2006) 01.166
4. 3 receptors for the activation of extracellular-regulated kinase. J. Biol. Chem. 279 (2004) 28304-28314
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utiliszing the principle of protein-dye binding. Anal. Biochem. 7 (1976) 248-254
6. 1A agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49 (2005) 996-1006
7. 2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 534 (2006) 63-70
8. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 (2002) 381-389
9. Burstein E.S., Ma J., Wong S., Gao Y., Pham E., Knapp A.E., Nash N.R., Olsson R., Davis R.E., Hacksell U., Weiner D.M., and Brann M.R. Intrinsic efficacy of antipsychotics at human d2, d3, and d4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a d2/d3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
10. 2 dopamine receptors. Mol. Pharmacol. 45 (1994) 51-60
11. 2 receptors. Biochem. Biophys. Res. Commun. 256 (1999) 33-40
12. 1A agonist actions. II. Preclinical behavioral effects. Neuropharmacology 39 (2000) 1211-1221
13. 2 dopamine receptor/G protein interaction. J. Biol. Chem. 276 (2001) 28667-28675
14. 3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol. Pharmacol. 56 (1999) 1025-1030
15. 3 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 361 (2000) 569-572
16. 1A receptors. Psychopharmacology 162 (2002) 168-177
17. 4 partial agonist properties: (III) activity in models of cognition and negative symptoms. Br. J. Pharmacol. 151 2 (2007) 266-277
18. 3 Receptor Antagonist: Neurochemical and Electrophysiological Studies In Vivo. Program No. 913.19 Abstract Viewer/Itinerary Planner (2005), Society for Neuroscience, Washington DC Online
19. 2L cell line: evidence for induction of ligand-specific receptor states. Mol. Pharmacol. 66 (2004) 97-105
20. o G proteins: evidence for agonist regulation of G protein selectivity. Br. J. Pharmacol. 138 (2003) 775-786
21. 3 receptor and chromosome identification. CR Séances Acad. Sci. Sér. III 311 (1990) 501
22. 2 receptor expressing neurons. Neuropsychopharmacology 20 (1999) 60-80
23. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch. Gen. Psychiatry. 54 (1997) 225-232
24. 3 receptor antagonists as therapeutic agents. DDT 10 (2005) 917-925
25. Kapur S., Zipursky R., Jones C., Remington G., and Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157 (2000) 514-520
26. 3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology 179 (2005) 567-575
27. Lawler C.P., Prioleau C., Lewis M.M., Mak C., Jiang D., Schetz J.A., Gonzalez A.M., Sibley D.R., and Mailman R.B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
28. B from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation. Trends Pharmacol. Sci. 14 (1993) 237-239
29. 3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45 (2003) 174-181
30. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27 (2003) 1159-1172
31. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT) (1A) receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
32. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293 (2000) 1063-1073
33. 3 receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 293 (2000) 1048-1062
34. Millan M.J., Di Cara B., Dekeyne A., Panayi F., De Groote L., Sicard D., Cistarelli L., Billiras R., and Gobert A. Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. J. Neurochem. 1004 4 (2007) 1047-1061
35. Missale C., Nash S.R., Robinson S.W., Jaber M., and Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 78 (1998) 189-225
36. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry. 10 (2005) 79-104
37. 35S]thio)-triphosphate binding and antibody study. Mol. Pharmacol. 55 (1999) 564-574
38. Newman-Tancredi A., Cussac D., Audinot V., Nicolas J.P., De Ceuninck F., Boutin J.A., and Millan M.J. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 303 (2002) 805-814
39. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 1-16
40. 3 receptor agonist. Nature 400 (1999) 371-375
41. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 60 (2003) 681-690
42. 3 receptor antagonist, SB-277011-A.J. Pharmacol. Exp. Ther. 294 (2000) 1154-1165
43. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
44. 3 receptors on learning and memory in the rat. Eur. J. Pharmacol. 336 (1997) 107-112
45. 2 receptor. Eur. J. Pharmacol. 225 (1992) 331-337
46. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Dis. 5 (2006) 25-43
47. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 779 (1998) 58-74
48. Urban, J.D., Vargas, G.A., von Zastrow, M., Mailman, R.B., 2006. Aripiprazole has functionally selective actions at dopamine D(2) receptor-mediated signaling pathways. Neuropsychopharmacology doi: 10.1038/sj.npp.1301071.
49. Wood M.D., Boyfield I., Nash D.J., Jewitt F.R., Avenell K.Y., and Riley G.J. Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur. J. Pharmacol. 407 (2000) 47-51
50. o subtype of G proteins in SH-SY5Y cells. Br. J. Pharmacol. 128 (1999) 1181-1188